Trial · NCT03372057
Results by group25
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 25
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate (ORR) as Assessed by the Investigator Using the Lugano Criteria | Dose Optimization Phase: Cohort 1 | 53.8 | 95% Confidence Interval 26.7 to 80.9 | percentage of participants | |
| Overall Response Rate (ORR) as Assessed by the Investigator Using the Lugano Criteria | Dose Optimization Phase: Cohort 2 | 53.8 | 95% Confidence Interval 26.7 to 80.9 | percentage of participants | |
| ORR as Assessed by the Independent Review Committee (IRC) Using the Lugano Criteria | Expansion Phase | 48.0 | 95% Confidence Interval 39.1 to 56.8 | percentage of participants | |
| Duration of Response (DOR) as Assessed by the Investigator Using the Lugano Criteria | Dose Optimization Phase: Cohort 1 | 4.22 | 95% Confidence Interval 1.87 to NA | month | |
| Duration of Response (DOR) as Assessed by the Investigator Using the Lugano Criteria | Dose Optimization Phase: Cohort 2 | 3.32 | 95% Confidence Interval 1.77 to NA | month | |
| Progression-free Survival (PFS) as Assessed by the Investigator Using the Lugano Criteria | Dose Optimization Phase: Cohort 1 | 3.55 | 95% Confidence Interval 1.05 to 8.54 | month | |
| Progression-free Survival (PFS) as Assessed by the Investigator Using the Lugano Criteria | Dose Optimization Phase: Cohort 2 | 3.55 | 95% Confidence Interval 1.81 to 13.14 | month | |
| Disease Control Rate (DCR) As Assessed by the Investigator Using the Lugano Criteria | Dose Optimization Phase: Cohort 1 | 61.5 | 95% Confidence Interval 35.1 to 88.0 | percentage of participants | |
| Disease Control Rate (DCR) As Assessed by the Investigator Using the Lugano Criteria | Dose Optimization Phase: Cohort 2 | 61.5 | 95% Confidence Interval 35.1 to 88.0 | percentage of participants | |
| DOR as Assessed by the IRC Using the Lugano Criteria | Expansion Phase | 7.9 | 95% Confidence Interval 6.4 to 21.00 | month | |
| PFS as Assessed by the IRC Using the Lugano Criteria | Expansion Phase | 3.4 | 95% Confidence Interval 1.8 to 3.9 | months | |
| DCR as Assessed by the IRC Using the Lugano Criteria | Expansion Phase | 49.6 | 95% Confidence Interval 40.8 to 58.4 | percentage of participants | |
| Overall Survival (OS) | Dose Optimization Phase: Cohort 1 | 6.70 | 95% Confidence Interval 5.22 to NA | month | |
| Overall Survival (OS) | Dose Optimization Phase: Cohort 2 | 10.58 | 95% Confidence Interval 6.67 to 44.62 | month | |
| Overall Survival (OS) | Expansion Phase | 12.4 | 95% Confidence Interval 8.4 to 22.7 | month | |
| Plasma Concentration of IPI-145 (Duvelisib) and IPI-656 (Metabolite) | Dose Optimization Phase: Cohort 1 | Duvelisib: Cycle 1, Day 15 | 1238.1 | Standard Deviation 787.53 | ng/mL |
| Plasma Concentration of IPI-145 (Duvelisib) and IPI-656 (Metabolite) | Dose Optimization Phase: Cohort 2 | Duvelisib: Cycle 1, Day 15 | 2070.0 | Standard Deviation 889.39 | ng/mL |
| Plasma Concentration of IPI-145 (Duvelisib) and IPI-656 (Metabolite) | Expansion Phase | Duvelisib: Cycle 1, Day 15 | 2873.7 | Standard Deviation 1709.15 | ng/mL |
| Plasma Concentration of IPI-145 (Duvelisib) and IPI-656 (Metabolite) | Dose Optimization Phase: Cohort 1 | Duvelisib: Cycle 2, Day 15 | 1492.5 | Standard Deviation 1019.10 | ng/mL |
| Plasma Concentration of IPI-145 (Duvelisib) and IPI-656 (Metabolite) | Expansion Phase | Duvelisib: Cycle 2, Day 15 | 2648.2 | Standard Deviation 1336.94 | ng/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03372057/results